AusBiotech CEO, Ms Lorraine Chiroiu, has announced she will hand over the leadership of AusBiotech, after more than five years at the helm and 15 years of successful and dedicated service to the organisation and the life sciences sector – effective from 15 December 2023.
Ms Chiroiu has been pivotal in the growth of the organisation and strengthened its position as the peak industry body for the biotechnology sector. Lorraine has been a fierce advocate for the sector, representing the industry to government bodies to maintain continuity of the Research and Development (R&D) Tax Incentive and shape policy that benefits all members of the Australian biotechnology community. She leaves a lasting legacy for the industry and the organisation in a strong financial position.
On behalf of the Board, AusBiotech Chair Mr Geoffrey Kempler remarked “Lorraine is a respected and dedicated leader and has made numerous and significant contributions to the biotechnology industry during her tenure at AusBiotech, most notably in her role as CEO. We are grateful and proud of Lorraine’s sustained service and loyalty to AusBiotech and sincerely thank her for her dedication and achievements.”
Ms Chiroiu has been a passionate leader in support of policy to drive the industry’s growth, as well as shaping the culture and financial performance of AusBiotech. She has been instrumental in a range of strategic policy campaigns, holding very successful conferences and events and attracting industry support. Her responsive and effective leadership during the pandemic enabled the organisation to adapt to the evolving challenges and continued achievement of impressive results.
The AusBiotech board has initiated a recruitment process for the CEO position.
